Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab with Chemotherapy and Sequential RT in Newly Diagnosed ES-SCLC
NCT06125041Phase 2Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Oct 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adebelizumab in small cell lung cancer (SCLC), sponsored by Shandong Provincial Qianfoshan Hospital. Started Oct 2023; status: recruiting.
02
Drugs
adebelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06125041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125041.